Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Temsirolimus (CCI-779, Torisel) Combined With Cetuximab (Erbitux) in Cetuximab-Refractory Colorectal Cancer

NCT00593060 is registered in ClinicalTrials.gov with Jeffrey W. Clark, MD as lead sponsor.

NCT NCT00593060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00593060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Temsirolimus (CCI-779, Torisel) Combined With Cetuximab (Erbitux) in Cetuximab-Refractory Colorectal Cancer
Lead sponsor
Jeffrey W. Clark, MD
Phase
Phase 1
Overall status
Completed
Start date
November 1, 2007
Completion date
November 30, 2010
Enrollment
35 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal adenocarcinoma, colorectal cancer